Zevra Therapeutics (ZVRA) Projected to Post Earnings on Tuesday

Zevra Therapeutics (NASDAQ:ZVRA - Get Free Report) will likely be issuing its Q1 2025 quarterly earnings data after the market closes on Tuesday, May 13th. Analysts expect the company to announce earnings of ($0.21) per share and revenue of $16.96 million for the quarter.

Zevra Therapeutics (NASDAQ:ZVRA - Get Free Report) last released its quarterly earnings results on Tuesday, March 11th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.28). Zevra Therapeutics had a negative net margin of 342.63% and a negative return on equity of 159.54%. The company had revenue of $12.00 million for the quarter, compared to the consensus estimate of $8.93 million. On average, analysts expect Zevra Therapeutics to post $-2 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Zevra Therapeutics Stock Performance

Shares of NASDAQ ZVRA traded up $0.01 during trading on Monday, hitting $7.88. The company had a trading volume of 284,256 shares, compared to its average volume of 620,033. Zevra Therapeutics has a 12 month low of $4.20 and a 12 month high of $9.76. The company has a debt-to-equity ratio of 0.84, a quick ratio of 2.88 and a current ratio of 2.88. The firm has a market capitalization of $430.60 million, a P/E ratio of -3.99 and a beta of 1.87. The stock has a 50 day simple moving average of $7.52 and a 200 day simple moving average of $8.07.

Analyst Ratings Changes

ZVRA has been the topic of several analyst reports. Canaccord Genuity Group lifted their price target on shares of Zevra Therapeutics from $23.00 to $25.00 and gave the company a "buy" rating in a report on Thursday, March 13th. JMP Securities set a $18.00 target price on shares of Zevra Therapeutics in a research note on Wednesday, March 12th. Citigroup reiterated an "outperform" rating on shares of Zevra Therapeutics in a research note on Wednesday, March 12th. HC Wainwright restated a "buy" rating and issued a $20.00 price objective on shares of Zevra Therapeutics in a research report on Thursday, March 13th. Finally, Cantor Fitzgerald reiterated an "overweight" rating and set a $25.00 target price on shares of Zevra Therapeutics in a research report on Wednesday, March 12th. Eight analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Zevra Therapeutics currently has a consensus rating of "Buy" and a consensus target price of $22.29.

Insider Activity at Zevra Therapeutics

In related news, Director John B. Bode bought 10,000 shares of the company's stock in a transaction dated Wednesday, March 19th. The stock was purchased at an average price of $7.96 per share, for a total transaction of $79,600.00. Following the acquisition, the director now owns 40,000 shares in the company, valued at $318,400. This trade represents a 33.33% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Neil F. Mcfarlane sold 61,273 shares of the firm's stock in a transaction on Thursday, February 13th. The stock was sold at an average price of $7.86, for a total value of $481,605.78. Following the completion of the sale, the chief executive officer now owns 222,060 shares of the company's stock, valued at approximately $1,745,391.60. This represents a 21.63% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 85,773 shares of company stock valued at $674,176. 2.40% of the stock is owned by corporate insiders.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.